CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?

Bartoló‐Ibars, Ariadna; Uribe‐Herranz, Mireia; Muñoz-Sánchez, Guillermo; Arnaldos-Perez, Cristina; Ortiz-Maldonado, Valentín; Urbano-Ispizúa, Álvaro; Pascal, Mariona; Juan, Manel

doi:10.3390/cancers13184664

Cited by 13 publications

(11 citation statements)

References 69 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The possibility of long-term storage of cryopreserved leukapheresis product may be beneficial for pediatric patients with ALL and patients with high-risk non-Hodgkin lymphoma who have early r/r disease prior to additional salvage and bridging. Notably, if a patient is planning to proceed with allogeneic stem cell transplant (alloSCT) and requires CAR T-cell therapy for post-alloSCT relapse, it is unlikely that the leukapheresis product stored from pre-alloSCT would be utilized, and a fresh collection would be preferred [11,12]. The optimal timing for cryopreservation is as soon as possible after collection, but at most within 24 h of collection [10].…”

Section: Introductionmentioning

confidence: 99%

Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing

et al. 2022

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing

et al. 2022

View full text Add to dashboard Cite

“…Relapse and disease persistence after allo-HSCT resulting in treatment failure and death is another significant challenge in addition to the transplant-related toxicity. The reported adverse effects of allo-HSCT and CAR-T cell therapy are acute and chronic GVHD, graft failure, infections, prolonged cytopenias, neurotoxicity, and cytokine release syndrome [ 163 , 164 ].…”

Section: Challenges and Limitationsmentioning

confidence: 99%

CAR-T cell combination therapy: the next revolution in cancer treatment

et al. 2022

View full text Add to dashboard Cite

In recent decades, the advent of immune-based therapies, most notably Chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer treatment. The promising results of numerous studies indicate that CAR-T cell therapy has had a remarkable ability and successful performance in treating blood cancers. However, the heterogeneity and immunosuppressive tumor microenvironment (TME) of solid tumors have challenged the effectiveness of these anti-tumor fighters by creating various barriers. Despite the promising results of this therapeutic approach, including tumor degradation and patient improvement, there are some concerns about the efficacy and safety of the widespread use of this treatment in the clinic. Complex and suppressing tumor microenvironment, tumor antigen heterogeneity, the difficulty of cell trafficking, CAR-T cell exhaustion, and reduced cytotoxicity in the tumor site limit the applicability of CAR-T cell therapy and highlights the requiring to improve the performance of this treatment. With this in mind, in the last decade, many efforts have been made to use other treatments for cancer in combination with tuberculosis to increase the effectiveness of CAR-T cell therapy, especially in solid tumors. The combination therapy results have promising consequences for tumor regression and better cancer control compared to single therapies. Therefore, this study aimed to comprehensively discuss different cancer treatment methods in combination with CAR-T cell therapy and their therapeutic outcomes, which can be a helpful perspective for improving cancer treatment in the near future.

show abstract

“…One promising ACT treatment is the use of CAR-T cell, where T lymphocytes are genetically modified to express chimeric antigen receptors that recognize a specific surface tumor antigen. CAR -T cells have the main advantage of being non-MHC II restricted, so they can be administered from healthy allogenic donors, and they are still effective in cancers with down-regulation of MHCII [ 121 , 122 , 123 ]. However, despite the success of CAR-T CD19 cell therapy in lymphoproliferative diseases, the results in solid tumors, including melanoma, have been disappointing [ 124 , 125 ].…”

Section: Immunotherapeutic Strategiesmentioning

confidence: 99%

Companion Animal Model in Translational Oncology; Feline Oral Squamous Cell Carcinoma and Canine Oral Melanoma

Giuliano

2021

Biology

View full text Add to dashboard Cite

Companion animals with naturally occurring cancers can provide an advantageous model for cancer research and in particular anticancer drug development. Compared to commonly utilized mouse models, companion animals, specifically dogs and cats, share a closer phylogenetical distance, body size, and genome organization. Most importantly, pets develop spontaneous, rather than artificially induced, cancers. The incidence of cancer in people and companion animals is quite similar and cancer is the leading cause of death in dogs over 10 years of age. Many cancer types in dogs and cats have similar pathological, molecular, and clinical features to their human counterparts. Drug toxicity and response to anti-cancer treatment in dogs and cats are also similar to those in people. Companion animals share their lives with their owners, including the environmental and socioeconomic cancer-risk factors. In contrast to humans, pets have a shorter life span and cancer progression is often more rapid. Clinical trials in companion animals are cheaper and less time consuming compared to human trials. Dogs and cats with naturally occurring cancers are an ideal and unique model for human cancer research. Model selection for the specific type of cancer is of pivotal importance. Although companion animal models for translational research have been reviewed previously, this review will try to summarize the most important advantages and disadvantages of this model. Feline oral squamous cell carcinoma as a model for head and neck squamous cell carcinoma and canine oral melanoma as a model for mucosal melanoma and immunotherapy in people will be discussed as examples.

show abstract

CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?

Cited by 13 publications

References 69 publications

Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing

Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing

CAR-T cell combination therapy: the next revolution in cancer treatment

Companion Animal Model in Translational Oncology; Feline Oral Squamous Cell Carcinoma and Canine Oral Melanoma

Contact Info

Product

Resources

About